



HOKKAIDO UNIVERSITY

Title	The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression
Author(s)	Ishikawa, Shuhei; Yamamura, Ryodai; Hashimoto, Naoki et al.
Citation	Progress in neuro-psychopharmacology & biological psychiatry, 113, 110453 https://doi.org/10.1016/j.pnpbp.2021.110453
Issue Date	2022-03-08
Doc URL	https://hdl.handle.net/2115/88237
Rights	© 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	https://creativecommons.org/licenses/by-nc-nd/4.0/
Type	journal article
File Information	Ishikawa_et_al_Manuscript_revise.pdf



1 **The type rather than the daily dose or number of antipsychotics affects the incidence of**
2 **hyperglycemic progression**

3

4 Shuheï Ishikawa, PhD^a, Ryodai Yamamura, PhD^b, Naoki Hashimoto, PhD, MD^{c, *}, Ryo

5 Okubo, PhD, MD^d, Ryo Sawagashira, MD^{c, e}, Yoichi M. Ito, PhD^f, Norihiro Sato, PhD, MD^f,

6 Ichiro Kusumi, PhD, MD^c

7

8 ^a Department of Psychiatry, Hokkaido University Hospital, Sapporo, Japan, 060-8648

9 ^b Division of Biomedical Oncology, Institute for Genetic Medicine, Hokkaido University,

10 Sapporo, Japan, 060-8638

11 ^c Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo,

12 Japan, 060-8638

13 ^d Department of Clinical Epidemiology, Translational Medical Center, National Center of

14 Neurology and Psychiatry, Tokyo, Japan, 187-8551

15 ^e Department of Physiology, Hokkaido University Graduate School of Medicine, Sapporo,

16 Japan, 060-8638

17 ^f Hokkaido University Hospital Clinical Research & Medical Innovation Center, Sapporo,

18 Japan, 060-8648

19

20 *Corresponding author

21 Department of Psychiatry, Hokkaido University Graduate School of Medicine, 060-8638

22 North 15, West 7, Sapporo, Japan.

23 Phone/Fax: +81-11-706-5160/5081. E-mail: hashinao@med.hokudai.ac.jp

24

25 **Abbreviations¹**

26

¹ BMI, body mass index; CPZ, chlorpromazine equivalent; CI, confidence interval; GVIF, generalized variance inflation factor; HDL, high-density lipoprotein; HbA1c, glycated hemoglobin; histamine 1, H₁; HR, hazard ratio; muscarinic 1, M₁; muscarinic 3, M₃; serotonin 2C, 5-HT_{2C}, s.d.; standard deviation.

27 ABSTRACT

28 There have been concerns that antipsychotics increase the incidence of
29 hyperglycemic progression. Many factors have been suggested to contribute to the risk of
30 antipsychotic-induced hyperglycemic progression, including the type, daily dose, and number
31 of antipsychotics; however, few studies have examined these relationships. This study aimed
32 to examine the affect of antipsychotic treatment-associated factors on hyperglycemic
33 progression, after adjustment for the affect of background factors suggested to be associated
34 with hyperglycemic progression. This was a nationwide, multicenter, prospective cohort study
35 examining the incidence of hyperglycemic progression during a 12 mo period following the
36 initiation of newly prescribed antipsychotic medication. Demographic data, medication
37 history, and blood test values were collected from 631 study participants with normal blood
38 glucose levels at baseline for 12 mo. The primary endpoint (incidence of hyperglycemic
39 progression) was defined as progression from normal to prediabetic or probable diabetic
40 status, and was evaluated based on the Japanese monitoring guidance in patients with
41 schizophrenia. To further examine the affect of antipsychotics on glucose metabolism over
42 time, we examined changes in HbA1c levels 3, 6, and 12 mo after the initiation of treatment
43 with each antipsychotic. We found that treatment with zotepine and clozapine was associated
44 with a significantly high incidence of hyperglycemic progression. Furthermore, changes in
45 HbA1c levels 6 mo after the initiation of zotepine treatment were significantly higher than

46 those following blonanserin and haloperidol treatments. In contrast, there was no significant
47 difference in the change in total cholesterol, triglycerides, HDL cholesterol, and BMI during
48 the same period. Moreover, the “daily dose” and “number” of antipsychotics did not show an
49 association with the incidence of hyperglycemic progression. However, in a post hoc analysis
50 in which the antipsychotics were divided into two groups according to the strength of
51 blockade of H₁, M₁, M₃, and 5-HT_{2C} receptors, the incidence of hyperglycemic progression
52 was higher in the medium- and high-daily dose groups than in the low-daily dose group in the
53 antipsychotic group with strong blockade of these receptors. Our study indicated that the type
54 of antipsychotic had a greater affect on the incidence of hyperglycemic progression than the
55 daily dose of antipsychotics or their number. Among these, zotepine was most likely to
56 increase the incidence of hyperglycemic progression, suggesting the need for caution when
57 these antipsychotics are prescribed.

58

59 **Keywords:** antipsychotics, zotepine, hyperglycemic progression, daily dose, polypharmacy

60

61 1. INTRODUCTION

62 Antipsychotics are widely used for the treatment of mental illnesses, such as
63 schizophrenia and bipolar disorder (Huhn et al., 2019; Lindström et al., 2017). However, it
64 has been reported that antipsychotics increase the risk of metabolic abnormalities, such as
65 hyperglycemia, hyperlipidemia, and weight gain, consequently interfering with the mortality
66 reduction effect of antipsychotics (Johnsen and Kroken, 2012; Olfson et al., 2015; Taipale et
67 al., 2018; Zagozdzon et al., 2016).

68 Among the metabolic abnormalities, hyperglycemia is a major symptom of diabetes
69 and metabolic syndrome, and its presence has been shown to lead to acute and chronic
70 complications, increasing the mortality of patients and having a negative affect on the
71 prognosis of patients treated with antipsychotics (Fizelova et al., 2014; Marcovecchio, 2017;
72 Wu et al., 2015). Although the mechanisms underlying abnormalities in glucose metabolism
73 caused by antipsychotics are still unknown, there are two major hypotheses about the
74 mechanisms: 1) development of insulin resistance due to hyperinsulinemia, hypertension, and
75 hyperlipidemia caused by obesity, and 2) reduction in insulin secretion due to direct action on
76 pancreatic β -cells (Holt, 2019; Kowalchuk et al., 2019; Starrenburg and Bogers, 2009).

77 Although the effect of a variety of different factors of antipsychotics, such as “type”,
78 “daily dose”, and “number”, on glucose metabolism have been examined in patients treated
79 with antipsychotics, the results have not been consistent. Regarding the types of

80 antipsychotics, all antipsychotics have been found to contribute to the incidence of abnormal
81 glucose metabolism, although previous studies have reported that the incidence of abnormal
82 glucose metabolism varies according to the type of antipsychotics (Carnovale et al., 2021;
83 Holt, 2019; Marvanova, 2013; Pillinger et al. 2020; Zhang et al., 2017). Regarding the daily
84 dose of antipsychotics, several studies have reported that some antipsychotics increase the
85 risk of diabetes in a dose-dependent manner (Tu et al., 2019; Ulcickas Yood et al., 2011). In
86 contrast, other studies have reported no clear relationship between daily dose and the
87 incidence of diabetes in patients treated with antipsychotics (Henderson, 2001; Bechara,
88 2001). Regarding the number of antipsychotics, several studies have reported an association
89 between increased risk of diabetes and antipsychotic polypharmacy (Kessing et al., 2010;
90 Mamakou et al., 2018; Kato et al., 2015). In contrast, other studies have reported a lack of any
91 significant difference in the prevalence of diabetes between polypharmacy and monotherapy
92 with either first-generation antipsychotics or second-generation antipsychotics (Ijaz et al.,
93 2018; Correll et al., 2007).

94 Most of these studies have examined the risk of diabetes; however, few studies have
95 focused on hyperglycemia as a pre-stage of diabetes. Focusing on hyperglycemia progression
96 (progression from normoglycemia to prediabetes or probable diabetes) is important because
97 an intervention before the development of diabetes and metabolic syndrome is critical to
98 prevent their occurrence (McKenzie et al., 2021; Tabák et al., 2012). For these reasons, we

99 decided to examine the affect of "type", "daily dose", and "number" of antipsychotics on the
100 incidence of hyperglycemic progression. When examining the association between
101 antipsychotics and incidence of hyperglycemic progression, it is necessary to consider both
102 antipsychotic-related factors and the effects of glucose metabolism-related background
103 factors, such as age, sex, exercise, diet, and coadministration of non-antipsychotics (Guo et
104 al., 2006; Kusumi et al., 2018; Padwal et al., 2004; Preiss et al., 2011; Steardo et al., 2019;
105 Sugai et al., 2018; Vancampfort et al., 2016). Therefore, the present study examined the affect
106 of antipsychotic treatment-associated factors, such as type, daily dose, and number of drugs
107 on the incidence of hyperglycemic progression after adjusting for the affect of background
108 factors suggested to be associated with glucose metabolism using data from a nationwide,
109 multisite, prospective cohort study.

110

111 **2. METHODS**

112 ***2.1. Study design and population***

113 This was a nationwide prospective, observational cohort study registered at the
114 University Hospital Medical Information Network (UMIN) clinical trial register system
115 (registration number: UMIN000009868). Overall, 1323 patients with schizophrenia and
116 schizoaffective disorder, or bipolar disorder, who recently initiated treatment with

117 antipsychotics, were recruited from 44 sites in Japan (24 general hospitals, 17 psychiatric
118 hospitals, and 3 psychiatric clinics) as the study cohort between May 2013 and March 2015.

119

120 ***2.2. Definitions and criteria***

121 Study participants were diagnosed with schizophrenia, schizoaffective disorder, or
122 bipolar disorder by their physicians based on ICD-10 criteria (World Health Organization,
123 2013). Inclusion criteria were (i) initiation of a first- or second-generation antipsychotic
124 medication, (ii) a 12 mo history of medication prior to enrollment, and (iii) no diagnosis of
125 diabetes before baseline screening. Exclusion criteria were (i) patients with probable diabetes
126 or prediabetes at baseline screening. This study was conducted according to the guidelines of
127 the Declaration of Helsinki. All participants were fully briefed on study procedures and
128 provided written informed consent.

129

130 ***2.3. Measurements***

131 The initial screening captured the demographic characteristics of the participants,
132 including age, sex, duration of illness, outpatient and inpatient status, smoking and drinking
133 status, family history of illness (schizophrenia, bipolar disorder, major depressive disorder,
134 diabetes, and dyslipidemia), coexisting medical diagnoses (hypertension, heart disease, and
135 dyslipidemia), therapeutic interventions (dietary therapy, exercise therapy, and medical

136 therapy), and 12 mo medication history prior to enrollment and during the study period.
137 Baseline measurements, which included blood glucose (fasting or postprandial) or glycated
138 hemoglobin (HbA1c), serum lipids (total cholesterol, high-density lipoprotein (HDL)
139 cholesterol, and triglycerides), body weight, body mass index (BMI), were obtained prior to
140 the initiation of treatment with new antipsychotics. Baseline medication included the
141 administration of new antipsychotics, number of coadministered antipsychotics, daily dose of
142 antipsychotics, and coadministration of mood stabilizers, antidepressants, antilipidemic
143 agents, and antihypertensives.

144 The Japanese monitoring guidance in patients with schizophrenia (Kusumi et al.,
145 2011) classifies blood glucose levels as follows: (i) normal (fasting blood glucose <110
146 mg/dL, postprandial blood glucose <140 mg/dL, or HbA1c <6.0%), (ii) prediabetes (fasting
147 blood glucose of 110–125 mg/dL, postprandial blood glucose of 140–179 mg/dL, or HbA1c
148 of 6.0–6.4%), and (iii) probable diabetes (fasting blood glucose > 125 mg/dL, postprandial
149 blood glucose > 179 mg/dL, or HbA1c > 6.4%). Blood tests were scheduled in accordance
150 with the Japanese guidelines for blood glucose monitoring in patients with schizophrenia and
151 were conducted at 3, 6, and 12 mo for patients with normal blood glucose levels (Kusumi et
152 al., 2011).

153

154

155 *2.4. Statistical analyses*

156 The primary endpoint was hyperglycemic progression during 12 mo after new
157 initiation of antipsychotic medication. The incidence of hyperglycemic progression was
158 defined as progression from normal to prediabetes or probable diabetes according to the blood
159 glucose criteria described in the “Measurements” section of the methods. Time-to-event was
160 defined as the time interval between the date of new initiation of antipsychotic medication and
161 the date of hyperglycemic progression or the censor date of the last follow-up period. We
162 used Cox proportional hazard regression models (Cox, 1972) to assess whether the affect on
163 hyperglycemic progression differed between each factor associated with antipsychotic
164 medication (type, daily dose, and number of antipsychotics) in multivariable analysis adjusted
165 for available background factors reported to have an affect on hyperglycemic progression
166 (Kusumi et al., 2018; Koller and Doraiswamy, 2002; Mukherjee et al., 1996; Sweileh et al.,
167 2013).

168 Participant data associated with antipsychotic medication included newly initiated
169 antipsychotic medication (type of antipsychotics), number of antipsychotics, and daily dose of
170 antipsychotics in chlorpromazine equivalent (CPZ) (Inada et al., 2015). Participant data
171 related to hyperglycemic progression included sex, age, diagnosis (schizophrenia and
172 schizoaffective disorder or bipolar disorder), duration of illness, treatment status (out-patient
173 or in-patient), smoking status (current smoker or not), drinker status (current drinker or not),

174 family history of schizophrenia, bipolar disorder, major depression, diabetes, and heart
175 disease, coexisting diagnoses of dyslipidemia, hypertension, and heart disease, therapeutic
176 interventions and concomitant medication, baseline measurements including BMI (< 25
177 versus ≥ 25), total cholesterol (<220 versus ≥ 220 mg/dL), HDL cholesterol (<40 versus ≥ 40
178 mg/dL), and triglycerides (<150 versus ≥ 150 mg/dL) (Kusumi et al., 2018). These variables
179 were acquired for each participant at baseline by psychiatrists in charge. Hazard ratios (HR)
180 and 95% confidence intervals (CI) for the Cox univariate factors were calculated using a Cox
181 proportional hazards model with each of the following groups as the reference group. The
182 reference group for the type of antipsychotics was initiation of aripiprazole, which is
183 considered to have the lowest risk of hyperglycemic progression among the antipsychotics
184 included in the study (Pillinger et al. 2020; Zhang et al., 2017; Carnovale et al., 2021). The
185 number of coadministered antipsychotics and the daily dose (as CPZ) of antipsychotics were
186 classified into three levels based on previous reports (Mamakou et al., 2018; Wubeshet et al.,
187 2019), and the reference group was the number of coadministered antipsychotics = 0 and 300
188 <daily dose (as CPZ) of antipsychotics, which is considered to have the lowest incidence of
189 hyperglycemic progression. We checked the multicollinearity of the independent variables to
190 assess their validity. Multicollinearity was assessed by calculating the degree of freedom
191 adjusted for generalized variance inflation factors (GVIF) (Fox and Monette, 1992). To

192 further confirm the robustness of the results, the same tests were conducted in the groups
193 stratified by the duration of newly initiated antipsychotic medication (3, 6, and 12 mo).

194 Furthermore, we conducted two post hoc analyses to further assess the affect of type
195 of antipsychotic on hyperglycemic progression. A post hoc analysis was conducted to
196 determine whether the affect of daily dose and number of antipsychotics on hyperglycemic
197 progression depends on the pharmacological properties of the antipsychotics.

198 Pharmacological properties related to abnormalities in glycolipid metabolism were defined as
199 blocking effects on histamine 1 (H₁), muscarinic 1 (M₁), muscarinic 3 (M₃), and serotonin 2C
200 (5-HT_{2C}) receptors from previous reports (Chen et al., 2017; Montastruc et al., 2015;
201 Reynolds and Kirk, 2010; Silvestre and Prous, 2005; Starrenburg and Bogers, 2009; Weston-
202 Green et al., 2013). Clozapine, olanzapine, quetiapine, zotepine, and levomepromazine were
203 defined as antipsychotics with high affinity for H₁, M₁, M₃ and 5-HT_{2C} receptors, while
204 aripiprazole, blonanserin, risperidone, perospirone, paliperidone, fluphenazine, haloperidol,
205 and sulpiride were defined as antipsychotics with low affinity for these receptors (Kusumi et
206 al., 2014; Silvestre and Prous, 2005). The participants were divided into two groups: those
207 newly prescribed antipsychotics with high affinity for these receptors and those newly
208 prescribed antipsychotics with low affinity for these receptors. Subsequently, Cox regression
209 analysis was performed for each group in the same way as the main analysis. Another post
210 hoc analysis was conducted to assess the affect of each antipsychotic medication on


211 abnormalities in glycolipid metabolism over time. This analysis examined differences in
212 changes over time in markers related to glycolipid metabolism (HbA1c, total cholesterol,
213 HDL cholesterol, triglycerides, and BMI) at 3, 6, or 12 mo after initiation of each
214 antipsychotic medication. In this analysis, the significance of the differences in changes in
215 markers between antipsychotics at each timepoint was assessed using the Kruskal-Wallis test
216 and Steel-Dwass post-test. All statistical analyses were performed using the dplyr packages
217 run on R statistics 4.0.2. All probability values were two-tailed, and the significance level was
218 set at $P < 0.05$.

219

220 **3. RESULTS AND STATISTICAL ANALYSES**

221 ***3.1. Participants and baseline characteristics***

222 The cohort recruited 1323 participants with schizophrenia and schizoaffective
223 disorder or bipolar disorder who had started treatment with a first- or second-generation
224 antipsychotic. Among them, 77 declined to participate, 41 failed to meet the inclusion criteria,
225 and 3 were rejected as duplicate enrolments. Additionally, 160 participants were excluded as
226 prediabetes or probable diabetes cases, while 407 participants were excluded due to missing
227 data at baseline monitoring, and 4 participants were excluded because they were initiated on
228 antipsychotics (chlorpromazine and fluphenazine), which are rarely prescribed. Finally, 631
229 participants were included in the analysis, as shown in Figure 1.



231

232 **Figure 1. Flowchart of study participants.** The number of participants excluded from the

233 study due to missing data for each factor is shown. We noticed the overlap of exclusion

234 criteria in some study participants. Type and number of excluded data were duration of illness
235 ($n = 92$), smoking ($n = 20$), drinking ($n = 23$), family history of schizophrenia and
236 schizoaffective disorder ($n = 113$), family history of bipolar disorder ($n = 127$), family history
237 of major depression ($n = 131$), family history of diabetes ($n = 176$), family history of
238 dyslipidemia ($n = 229$), coexisting dyslipidemia ($n = 5$), coexisting hypertension ($n = 6$)
239 coexisting heart disease ($n = 6$), dietary therapy ($n = 2$), exercise therapy ($n = 1$), total
240 cholesterol ($n = 25$), HDL cholesterol ($n = 50$), triglycerides ($n = 19$), chlorpromazine
241 equivalent dose ($n = 52$), and coadministered antilipidemic agents ($n = 1$).

242 The characteristics of participants are shown in Table 1. Of the 631 participants, we
243 observed that 94 progressed to hyperglycemia during the study term. Among them, 523
244 (82.9%) participants were diagnosed with schizophrenia or schizoaffective disorder and 108
245 (17.1%) with bipolar disorder. Administered antipsychotics included aripiprazole (29.8%),
246 olanzapine (14.4%), quetiapine (11.4%), risperidone (8.2%), blonanserin (7.4%), perospirone
247 (7.1%), levomepromazine (6.8%), paliperidone (3.5%), haloperidol (3.3%), clozapine (3.2%),
248 sulpiride (2.9%), and zotepine (1.9%). At the start of the study, 194 participants (30.7%) were
249 treated with antipsychotic monotherapy, 218 participants (34.5%) were treated with dual
250 antipsychotic therapy, and 219 participants (34.7%) were treated with a concomitant therapy
251 of 3 or more antipsychotics. The cohort included 238 participants (37.7%) treated with
252 antipsychotics at a mean daily dose (as CPZ) of 300 mg or less, 159 participants (25.2%)

253 treated with antipsychotics at a mean daily dose of 300 to 600 mg, and 234 participants
 254 (37.1%) treated with antipsychotics at a mean daily dose of 600 mg or more. The mean daily
 255 dose of antipsychotic medication taken by all participants in the study was 589 mg.
 256

257 **Table 1. Participant characteristics, baseline monitoring, and medication**

	Values		
	Total (n = 631)	Hyperglycemic progression	
		No (n = 537)	Yes (n = 94)
<i>Baseline characteristics</i>			
Men/women, n (%)	265 (42.0) / 366 (58.0)	227 (42.3) / 310 (57.8)	38 (40.4) / 56 (59.6)
Age, n (%)			
<40 years	274 (43.4)	239 (44.5)	20 (21.3)
40–60 years	276 (43.7)	234 (43.6)	42 (44.7)
>60 years	81 (12.8)	64 (11.9)	17 (18.1)
Duration of illness, n (%)			
<1.5 years	116 (18.4)	96 (17.9)	35 (37.2)
1.5–10 years	165 (26.1)	145 (27.0)	20 (21.3)
11–20 years	173 (27.4)	148 (27.6)	25 (26.6)
>20 years	177 (28.1)	148 (27.6)	29 (30.9)
Diagnosis, n (%)			
Schizophrenia	454 (72.0)	386 (71.9)	68 (72.3)
Schizoaffective disorder	69 (10.9)	58 (10.8)	11 (11.7)
Bipolar disorder	108 (17.1)	93 (17.3)	15 (16.0)
Out-patient/in-patient, n (%)	328 (52.0) / 303 (48.0)	277 (51.6) / 260 (48.4)	51 (54.3) / 43 (45.7)
Smoking, n (%)	200 (31.7)	169 (31.5)	31 (33.0)
Drinking, n (%)	118 (18.7)	100 (18.6)	18 (19.1)
Familial history, n (%)			
Schizophrenia	84 (13.3)	75 (14.0)	9 (9.6)

Bipolar disorder	19 (3.0)	18 (3.4)	1 (1.1)
Major depression	63 (10.0)	51 (9.5)	12 (12.8)
Diabetes	129 (20.4)	109 (20.3)	20 (21.3)
Dyslipidemia	72 (11.4)	62 (11.5)	10 (10.6)
Coexisting medical diagnoses, n (%)			
Dyslipidemia	77 (12.2)	58 (10.8)	19 (20.2)
Hypertension	58 (9.2)	41 (7.6)	17 (18.1)
Heart disease	23 (3.6)	18 (3.4)	5 (5.3)
Therapeutic interventions, n (%)			
Dietary therapy	24 (3.8)	19 (3.5)	5 (5.3)
Exercise therapy	16 (2.5)	11 (2.0)	5 (5.3)
Medical therapy	22 (3.5)	19 (3.5)	3 (3.2)

Monitoring at baseline

Body weight, kg: mean (s.d.)	62 (14.5)	62 (14.2)	64 (15.9)
Body mass index, kg/m ² : mean (s.d.)	24 (4.7)	23 (4.6)	25 (5.4)
Body mass index: ≥ 25 , n (%)	209 (33.1)	168 (31.3)	41 (43.6)
Fasting blood glucose, mg/dL: mean (s.d.)	88 (9.4)	88 (9.4)	91 (9.6)
Postprandial blood glucose, mg/dL: mean (s.d.)	99 (15.5)	98 (15.4)	104 (15.1)
HbA1c, %: mean (s.d.)	5 (0.3)	5 (0.3)	5 (0.4)
Total cholesterol, mg/dL: mean (s.d.)	187 (38.3)	186 (38.9)	192 (34.7)
Total cholesterol: ≥ 220 , n (%)	121 (19.2)	103 (19.2)	18 (19.1)
HDL cholesterol, mg/dL: mean (s.d.)	58 (17.5)	59 (17.9)	56 (14.8)
HDL cholesterol: < 40 , n (%)	71 (11.3)	59 (11.0)	12 (12.8)
Triglyceride, mg/dL: mean (s.d.)	117 (81.3)	115 (83.9)	128 (63.8)
Triglyceride: ≥ 150 , n (%)	27 (4.3)	23 (4.3)	4 (4.3)

Baseline medications

Newly initiated antipsychotics, n (%)			
Aripiprazole	188 (29.8)	164 (30.5)	24 (25.5)
Olanzapine	91 (14.4)	75 (14.0)	16 (17.0)
Quetiapine	72 (11.4)	66 (12.3)	6 (6.4)
Risperidone	52 (8.2)	44 (8.2)	8 (8.5)
Blonanserin	47 (7.4)	40 (7.4)	7 (7.4)
Perospirone	45 (7.1)	35 (6.5)	10 (10.6)
Levomepromazine	43 (6.8)	37 (6.9)	6 (6.4)

Paliperidone	22 (3.5)	21 (3.9)	1 (1.1)
Haloperidol	21 (3.3)	20 (3.7)	1 (1.1)
Clozapine	20 (3.2)	14 (2.6)	6 (6.4)
Sulpiride	18 (2.9)	15 (2.8)	3 (3.2)
Zotepine	12 (1.9)	6 (1.1)	6 (6.4)
Number of coadministered antipsychotics, n (%)			
0	194 (30.7)	169 (31.5)	25 (26.6)
1	218 (34.5)	188 (35.0)	30 (31.9)
≥2	219 (34.7)	180 (33.5)	39 (41.5)
Daily dose of antipsychotics (CPZ), n (%)			
<300 mg	238 (37.7)	207 (38.5)	31 (33.0)
300–600 mg	159 (25.2)	133 (24.8)	26 (27.7)
>600 mg	234 (37.1)	197 (36.7)	37 (39.4)
Daily dose of antipsychotics (CPZ), mg: mean (s.d.)	589 (576.5)	579 (566.7)	648 (629.6)
Coadministered non-antipsychotics, n (%)			
Mood stabilizers	141 (22.3)	123 (22.9)	18 (19.1)
Antidepressants	104 (16.5)	85 (15.8)	19 (20.2)
Antilipidemic agents	43 (6.8)	34 (6.3)	9 (9.6)
Antihypertensives	52 (8.2)	38 (7.1)	14 (14.9)

258 Footnote: A total of 631 participants for all factors shown in Table 1 except fasting ($n = 161$),
259 postprandial blood glucose ($n = 466$), and HbA1c ($n = 619$). In the non-hyperglycemic group,
260 there were a total of 537 participants for all factors shown in Table 1 except fasting ($n = 148$),
261 postprandial blood glucose ($n = 385$), and HbA1c ($n = 526$). In the hyperglycemic group,
262 there were a total of 94 participants for all factors shown in Table 1 except fasting ($n = 13$),
263 postprandial blood glucose ($n = 81$), and HbA1c ($n = 93$).

264

265 **3.2. Affect of baseline medication on the incidence of hyperglycemic progression**

266 Examination of the affect of each antipsychotic on the risk of hyperglycemic
267 progression using multivariate Cox regression analysis, including adjustment for baseline
268 factors and measurements, showed that initiation of treatment with clozapine (HR = 3.08,
269 95% CI = 1.05–9.02, $P = 0.04$) and zotepine (HR = 4.95, 95% CI = 1.72–14.26, $P = 0.003$)
270 was associated with a significantly higher incidence of hyperglycemic progression than that
271 with initiation of treatment with aripiprazole (Table 2). To confirm the affect of the duration
272 of newly initiated antipsychotic medication on the incidence of hyperglycemic progression,
273 additional analyses were conducted by stratifying the duration of these treatments into 3, 6,
274 and 12 mo. In both subgroups, zotepine showed a significantly higher incidence of
275 hyperglycemic progression than that with initiation of treatment with aripiprazole. In contrast,
276 there was a trend toward a higher rate of progression of hyperglycemia with clozapine in the
277 subgroup, although this was not statistically significant (Supplemental Table S1-3).

278 In contrast, with regard to the number of antipsychotics at the start of the study, we
279 did not detect any significant increase in the incidence of hyperglycemic progression in the
280 dual antipsychotic therapy and concomitant three or more antipsychotic therapy groups
281 compared with that in the antipsychotic monotherapy group (Table 2). Furthermore, with
282 regard to the daily dose calculated as CPZ, no significant increase was observed in the
283 incidence of hyperglycemic progression in the groups with a daily dose between 300 and 600
284 mg and those with a daily dose greater than 600 mg compared with those with a daily dose

285 less than 300 mg (Table 2). We checked the multicollinearity of independent variables
 286 through GVIF. We found that GVIF ranged from 1.02 to 2.50, indicating that
 287 multicollinearity was denied in this multiple regression analysis.

288 In a post hoc analysis in which antipsychotics were grouped according to the
 289 strength of blockade of H₁, M₁, M₃, and 5-HT_{2C} receptors, which are receptors associated with
 290 abnormal glucose metabolism, there was no association between the daily dose of
 291 antipsychotics and incidence of hyperglycemic progression in the antipsychotic group with
 292 weak blockade of these receptors (Supplemental Table S4). On the contrary, in the group of
 293 antipsychotics with strong blockade of these receptors, the incidence of hyperglycemic
 294 progression was significantly increased in the groups with a daily dose between 300 and 600
 295 mg (HR = 3.44, 95 % CI = 1.07–10.98, *P* = 0.037) and those with a daily dose greater than
 296 600 mg (HR = 4.15, 95 % CI = 1.19–14.43, *P* = 0.025) compared with that in the group with a
 297 daily dose less than 300 mg (Supplemental Table S4).

298

299 **Table 2. Affect of baseline medication on the incidence of hyperglycemic progression**

	<i>n</i>	Events	Multivariate analysis (<i>n</i> = 633)	
			Hazard ratio (95%CI)	<i>P</i>
<i>Baseline medications</i>				
Newly initiated antipsychotics				
Aripiprazole	188	24	Ref	
Olanzapine	91	16	1.11 (0.56 - 2.19)	0.768
Quetiapine	72	6	0.45 (0.17 - 1.18)	0.103

Risperidone	52	8	1.03	(0.43 - 2.44)	0.954
Blonanserin	47	7	0.89	(0.34 - 2.29)	0.805
Perospirone	45	10	1.49	(0.65 - 3.45)	0.348
Levomepromazine	43	6	0.95	(0.37 - 2.47)	0.921
Paliperidone	22	1	0.33	(0.04 - 2.63)	0.297
Haloperidol	21	1	0.43	(0.06 - 3.40)	0.427
Clozapine	20	6	3.08	(1.05 - 9.02)	0.040
Sulpiride	18	3	1.61	(0.43 - 5.97)	0.476
Zotepine	12	6	4.95	(1.72 - 14.26)	0.003
Number of coadministered antipsychotics					
0	194	25	Ref		
1	218	30	1.02	(0.53 - 1.96)	0.960
≥2	219	39	1.15	(0.53 - 2.49)	0.718
Daily dose of antipsychotics (CPZ)					
<300	238	31	Ref		
300–600	159	26	1.43	(0.71 - 2.87)	0.311
>600	234	37	1.48	(0.70 - 3.10)	0.303

300

301 Footnote: All factors shown in Table 1 except body weight, body mass index, fasting and
302 postprandial blood glucose, HbA1c, total cholesterol, HDL cholesterol, and triglycerides were
303 adjusted.

304

305 ***3.3. Affect of baseline factors and measurements on the incidence of hyperglycemic***

306 ***progression***


307 Regarding the affect of baseline factors and measurements on incidence of
308 hyperglycemic progression, we noticed that being overweight (BMI greater than or equal to

309 25) (HR =1.70, 95% CI = 1.07–2.71, $P = 0.026$) was significantly associated with the
310 incidence of hyperglycemic progression (Supplemental Table S5).

311

312 ***3.4. Changes in markers related to glycolipid metabolism after initiation of antipsychotic***
313 ***medications***

314 To investigate the affect of antipsychotic medications on glycolipid metabolism over
315 time, we examined changes in HbA1c levels at 3, 6, and 12 mo after initiation of each
316 antipsychotic medication. Additionally, we analyzed total cholesterol, triglycerides, HDL
317 cholesterol, and BMI at 12 mo after initiation of the medication. The change in HbA1c levels
318 after 6 mo of zotepine treatment was significantly higher than that after blonanserin and
319 haloperidol treatment. In addition, the change in HbA1c levels after 6 mo of blonanserin
320 treatment was significantly lower than that after aripiprazole treatment (Figure 2 and
321 Supplemental Table S6). In contrast, there was no significant difference in the change in total
322 cholesterol, triglycerides, HDL cholesterol, and BMI between the antipsychotics at any
323 timepoint (Supplemental Table S7).



325

326 **Figure 2. Changes in HbA1c levels after initiation of antipsychotic medications.** Changes

327 from baseline in markers related to glycolipid metabolism (HbA1c, total cholesterol, HDL

328 cholesterol, triglycerides, and BMI) after initiation of each antipsychotic medication were

329 expressed as median \pm standard deviation. The difference in the change in HbA1c levels from

330 baseline at each time point was compared between the antipsychotics. Statistical analysis was

331 performed by Kruskal-Wallis test followed by Steel-Dwass test for post-hoc comparison. * $P <$

332 0.05 versus blonanserin, and haloperidol; # $P <$ 0.05 versus aripiprazole.

333

334 **4. DISCUSSION**

335 Our current study examined the affect of antipsychotic treatment-associated factors
336 (“type”, “daily dose”, and “number” of antipsychotics) on incidence hyperglycemic
337 progression in the real-world clinical setting. Our results showed that initiation of treatment
338 with zotepine and clozapine led to significantly higher incidence of hyperglycemic
339 progression than that with aripiprazole treatment. In contrast, the “daily dose” and “number”
340 of antipsychotics were not associated with the risk of hyperglycemic progression in this study.
341 However, in a post hoc analysis of only participants who had initiated treatment with
342 antipsychotics that strongly blocked H₁, M₁, M₃, and 5-HT_{2C} receptors, the incidence of
343 hyperglycemic progression was significantly higher in medium- and high-daily dose groups
344 than in the low-daily dose group. Furthermore, the change in HbA1c levels after 6 mo of
345 initiation of zotepine treatment was significantly higher than that after blonanserin or
346 haloperidol treatment. In contrast, there were no significant differences in total cholesterol,
347 triglycerides, HDL cholesterol, and BMI between the antipsychotics at any timepoint.

348 Treatment with both zotepine and clozapine was associated with a higher incidence
349 of hyperglycemic progression compared with that in placebo, as recently reported in a
350 network meta-analysis of controlled studies (Pillinger et al. 2020). Our current study showed
351 that these two antipsychotics were associated with a higher incidence of hyperglycemic
352 progression even in real-world clinical settings. It has been reported that blockade of central
353 5-HT_{2C} and H₁ receptors leads to the development of insulin resistance and direct blockade of

354 M₃ receptors in pancreatic β -cells leads to reduction of insulin secretion (Holt, 2019;
355 Kowalchuk et al., 2019; Starrenburg and Bogers, 2009). As zotepine and clozapine are known
356 to exhibit these pharmacological properties (Holt, 2019; Yonemura et al., 1998; Gardner et
357 al., 2005; Starrenburg and Bogers, 2009; Kroeze et al., 2003; Philibin et al., 2009), the results
358 of our study were further supported from this aspect. Among them, zotepine has consistently
359 been shown to increase the risk of hyperglycemic progression in our study. Furthermore,
360 participants who initiated zotepine treatment had an increased incidence of hyperglycemic
361 progression without lipid abnormalities or weight gain. These findings suggest that zotepine
362 may cause hyperglycemic progression in a short term by reducing insulin secretion via
363 blockade of M₃ receptor. In contrast, olanzapine, quetiapine, and levomepromazine, which
364 were included in this study and have these pharmacological properties (Holt, 2019; Yonemura
365 et al., 1998; Gardner et al., 2005; Starrenburg and Bogers, 2009; Kroeze et al., 2003; Philibin
366 et al., 2009), were shown to not significantly increase the incidence of hyperglycemic
367 progression. Levomepromazine was prescribed at lower doses than other antipsychotics
368 (Supplemental Table S8); therefore, it might not have had sufficient pharmacological action
369 to induce the hyperglycemic progression in the study. Although olanzapine and quetiapine
370 have been reported in various studies to have an increased the incidence of hyperglycemic
371 progression, the results of a recently reported network meta-analysis showed that the risk for
372 elevated blood glucose levels in patients treated with these antipsychotics was not significant

373 compared with those treated with placebo (Pillinger et al. 2020). In addition, olanzapine and
374 quetiapine are contraindicated in patients with a history of diabetes in Japan. Therefore,
375 physicians tend to avoid prescribing them to patients at risk for hyperglycemic progression.
376 As a result, the incidence of hyperglycemic progression following treatment with olanzapine
377 and quetiapine observed in our study might be lower than the inherent risk.

378 The results of this study showed that the “daily dose” and “number” of
379 antipsychotics were not associated with the risk of hyperglycemic progression in this study.
380 However, in a post hoc analysis of only participants who initiated antipsychotics with potent
381 blockade of H₁, M₁, M₃, and 5HT_{2c} receptors showed that higher daily doses increased the
382 incidence of hyperglycemic progression, and there may be a dose-dependent increase in the
383 incidence of hyperglycemic progression following treatment with antipsychotics with these
384 pharmacological properties. A previous report has shown that there is a significant correlation
385 between the incidence of diabetes and receptor occupancy of H₁, muscarinic acetylcholine,
386 and 5-HT_{2c}; our results support these findings (Matsui-Sakata et al., 2005).

387 There were several limitations to this study. First, the independent variables assessed
388 in this study for their affect on hyperglycemic progression were obtained at the time of the
389 initiation of new antipsychotic medications. As such, they do not necessarily reflect the status
390 of treatment, as this might have changed after the initiation of the study. However, many
391 newly initiated antipsychotics were continuously administered for a long period of time

392 during the study, and their daily doses did not change considerably between the initiation and
393 end of the study (Supplemental Table S8). Moreover, the results were robust in a sensitivity
394 analysis of the group that had been on long-term treatment with newly initiated antipsychotics
395 (Supplemental Table S1-3). Second, the present study did not exclude the effect of drug-drug
396 interactions. Because antipsychotics are metabolized by a variety of drug-metabolizing
397 enzymes, including cytochrome P450 (CYP) 3A4, 1A2, and 2D6, the incidence of
398 hyperglycemic progression might have been altered by the concomitant use of drugs that
399 inhibit or induce metabolism. This study confirmed the affects of mood stabilizers and
400 antidepressants, which may cause drug interactions with antipsychotics, but did not show any
401 affect on the incidence of hyperglycemic progression. Third, a 1-y follow-up period might not
402 have been sufficient to observe the incidence of hyperglycemic progression in participants.
403 However, 1 y might have been long enough compared with the timeline used in many
404 previous studies (Pillinger et al. 2020; Zhang et al., 2017; Ulcickas Yood et al., 2011). Fourth,
405 although race has been reported to be a risk for diabetes, this study included only Japanese
406 subjects. Therefore, further studies should replicate our results with races other than Japanese.

407

408 **5. CONCLUSION**

409 The study was the first to examine the affect of the type, number, and daily dose of
410 antipsychotics on the incidence of hyperglycemic progression in real world clinical settings,

411 after adjustment for the affect of abnormal glucose metabolism-associated background
412 factors. We found that the type of antipsychotics had a greater affect on the incidence of
413 hyperglycemic progression than the daily dose of antipsychotics or their number.
414 Furthermore, among the antipsychotics, zotepine was found to increase the incidence of
415 hyperglycemic progression. These results suggested that caution should be exercised
416 regarding the incidence of hyperglycemic progression when this antipsychotic is prescribed.

417

418 **ACKNOWLEDGMENTS**

419 We are grateful to all of the participants and their families for their time and interest in this
420 study. We would like to thank Editage (<http://www.editage.jp>) for English language editing.

421

422 **FUNDING**

423 This study was supported by the Hokkaido University under grant “Reifu”. The funding
424 source had no involvement in the design of the study, the collection, analysis and
425 interpretation of data, the writing of the report and the decision to submit the article for
426 publication.

427

428 **DECLARATION OF INTEREST**

429 S.I. has received personal fees from Janssen Pharmaceutical, Dainippon Sumitomo Pharma,
430 Eisai, and MeijiSeika Pharma, and has received research/grant support from Eli Lilly. N.H.
431 has received personal fees from Janssen Pharmaceutical, Yoshitomiyakuhin, Otsuka
432 Pharmaceutical, Dainippon Sumitomo Pharma, Novartis Pharma, and MeijiSeika Pharma.
433 I.K. has received honoraria from Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli
434 Lilly, Janssen Pharmaceutical, Lundbeck, Meiji Seika Pharma, Mochida Pharmaceutical,
435 MSD, Mylan, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer,
436 Shionogi, Shire, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Tsumura, and
437 Yoshitomiyakuhin, and has received research/grant support from Asahi Kasei Pharma,
438 Astellas, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Mochida
439 Pharmaceutical, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda
440 Pharmaceutical and Tanabe Mitsubishi Pharma. R.S., R.Y., R.O., Y.I. and N.S. declare that
441 there are no conflicts of interest in relation to the subject of this study.

442

443 **AUTHOR CONTRIBUTIONS**

444 Shuhei Ishikawa: Formal analysis, Investigation, Writing-Original Draft, Funding acquisition

445 Naoki Hashimoto: Formal analysis, Investigation, Writing-Original Draft

446 Ryodai Yamamura: Formal analysis, Writing-Original Draft

447 Ryo Okubo: Project administration, Investigation, Supervision

448 Ryo Sawagashira: Formal analysis, Supervision

449 Yoichi M Ito: Conceptualization, Formal analysis, Methodology, Supervision

450 Norihiro Sato: Conceptualization, Methodology, Supervision

451 Ichiro Kusumi: Conceptualization, Investigation, Methodology, Supervision

452

453 **DATA AVAILABILITY STATEMENT**

454 Data are not available due to the participants of this study not agreeing to have their data be

455 shared publicly.

456

457 **REFERENCES**

- 458 Bechara, C.I., Goldman-Levine, J.D., 2001. Dramatic worsening of type 2 diabetes mellitus
459 due to olanzapine after 3 years of therapy. *Pharmacotherapy* 21, 1444–1447
460 <https://doi:10.1592/phco.21.17.1444.34423>.
- 461 Carnovale, C., Lucenteforte, E., Battini, V., Mazhar, F., Fornili, M., Invernizzi, E., Mosini,
462 G., Gringeri, M., Capuano, A., Scavone, C., Nobile, M., Vantaggiato, C., Pisano, S.,
463 Bravaccio, C., Radice, S., Clementi, E., Pozzi, M., 2021. Association between the
464 glyco-metabolic adverse effects of antipsychotic drugs and their chemical and
465 pharmacological profile: A network meta-analysis and regression. *Psychol. Med.* 24,
466 1–13. <https://doi.org/10.1017/S0033291721000180>.
- 467 Chen, J, Huang, X.F., Shao, R., Chen, C., Deng, C., 2017. Molecular Mechanisms of
468 Antipsychotic Drug-Induced Diabetes. *Front Neurosci.* 11, 643.
469 <https://doi.org/10.3389/fnins.2017.00643>.
- 470 Correll, C.U., Frederickson, A.M., Kane, J.M., Manu, P., 2007. Does antipsychotic
471 polypharmacy increase the risk for metabolic syndrome?. *Schizophr. Res.* 89, 91–100.
472 <https://doi.org/10.1016/j.schres.2006.08.017>.
- 473 Cox, D.R., 1972. Regression models and life-tables. *J.R.Stat.Soc. B.* 34, 187–202.
- 474 Fizeleva, M., Cederberg, H., Stančáková, A., Jauhiainen, R., Vangipurapu, J., Kuusisto, J.,
475 Laakso, M., 2014. Markers of tissue-specific insulin resistance predict the worsening of

- 476 hyperglycemia, incident type 2 diabetes and cardiovascular disease. PLOS ONE 9,
477 e109772. <https://doi.org/10.1371/journal.pone.0109772>.
- 478 Fox, J., Monette, G., 1992. Generalized Collinearity Diagnostics. J. Am. Stat. Assoc. 87, 178-
479 183. <https://doi.org/10.1080/01621459.1992.10475190>.
- 480 Gardner, D.M., Baldessarini, R.J., Waraich, P., 2005. Modern antipsychotic drugs: A critical
481 overview. CMAJ 172, 1703–1711. <https://doi.org/10.1503/cmaj.1041064>.
- 482 Guo, J.J., Keck, P.E.Jr., Corey-Lisle, P.K., Li, H., Jiang, D., Jang, R., L'Italien, G.J., 2006.
483 Risk of diabetes mellitus associated with atypical antipsychotic use among patients
484 with bipolar disorder: A retrospective, population-based, case-control study. J. Clin.
485 Psychiatry 67, 1055-1061. <https://doi.org/10.4088/jcp.v67n0707>.
- 486 Henderson, D.C., 2001; Suppl 23:39-44. Clozapine: Diabetes mellitus, weight gain, and lipid
487 abnormalities. J. Clin. Psychiatry 62 Suppl 23, 39–44.
- 488 Holt, R.I.G., 2019. Association between antipsychotic medication use and diabetes. Curr.
489 Diab. Rep. 19, 96. <https://doi.org/10.1007/s11892-019-1220-8>.
- 490 Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N.,
491 Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., Leucht, S., 2019.
492 Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment
493 of adults with multi-episode schizophrenia: A systematic review and network meta-
494 analysis. Lancet 394, 939–951. [https://doi.org/10.1016/S0140-6736\(19\)31135-3](https://doi.org/10.1016/S0140-6736(19)31135-3).

- 495 Ijaz, S., Bolea, B., Davies, S., Savović, J., Richards, A., Sullivan, S., Moran, P., 2018.
496 Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: A review of
497 systematic reviews. *BMC Psychiatry* 18, 482–492. [https://doi.org/10.1186/s12888-018-](https://doi.org/10.1186/s12888-018-1848-y)
498 [1848-y](https://doi.org/10.1186/s12888-018-1848-y).
- 499 Inada, T., Inagaki, A., 2015. Psychotropic dose equivalence in Japan. *Psychiatry Clin.*
500 *Neurosci.* 69, 440–447. <https://doi.org/10.1111/pcn.12275>.
- 501 Johnsen, E., Kroken, R.A., 2012. Drug treatment developments in schizophrenia and bipolar
502 mania: Latest evidence and clinical usefulness. *Ther. Adv. Chronic Dis.* 3, 287–300.
503 <https://doi.org/10.1177/2040622312462275>.
- 504 Kato, Y., Umetsu, R., Abe, J., Ueda, N., Nakayama, Y., Kinosada, Y., Nakamura, M., 2015.
505 Hyperglycemic adverse events following antipsychotic drug administration in
506 spontaneous adverse event reports. *J. Pharm. Heal. Care Sci.* 1, 15.
507 <https://doi.org/10.1186/s40780-015-0015-6>.
- 508 Kessing, L.V., Thomsen, A.F., Mogensen, U.B., Andersen, P.K., 2010. Treatment with
509 antipsychotics and the risk of diabetes in clinical practice. *Br. J. Psychiatry* 197, 266–
510 271. <https://doi.org/10.1192/bjp.bp.109.076935>.
- 511 Koller, E.A., Doraiswamy, P.M., 2002. Olanzapine-associated diabetes mellitus.
512 *Pharmacotherapy* 22, 841–852. <https://doi.org/10.1592/phco.22.11.841.33629>.

- 513 Kowalchuk, C., Castellani, L.N., Chintoh, A., Remington, G., Giacca, A., Hahn, M.K., 2019.
514 Antipsychotics and glucose metabolism: How brain and body collide. *Am. J. Physiol.*
515 *Endocrinol. Metab.* 316, E1–E15. <https://doi.org/10.1152/ajpendo.00164.2018>.
- 516 Kroeze, W.K., Hufeisen, S.J., Popadak, B.A., Renock, S.M., Steinberg, S., Ernsberger, P.,
517 Jayathilake, K., Meltzer, H.Y., Roth, B.L., 2003. H1-histamine receptor affinity
518 predicts short-term weight gain for typical and atypical antipsychotic drugs.
519 *Neuropsychopharmacology* 28, 519–526. <https://doi.org/10.1038/sj.npp.1300027>.
- 520 Kusumi, I., Arai, Y., Okubo, R., Honda, M., Matsuda, Y., Matsuda, Y., Tochigi, A., Takekita,
521 Y., Yamanaka, H., Uemura, K., Ito, K., Tsuchiya, K., Yamada, J., Yoshimura, B.,
522 Mitsui, N., Matsubara, S., Segawa, T., Nishi, N., Sugawara, Y., Kako, Y., Shinkawa, I.,
523 Shinohara, K., Konishi, A., Iga, J., Hashimoto, N., Inomata, S., Tsukamoto, N., Ito, H.,
524 Ito, Y.M., Sato, N., 2018. Predictive factors for hyperglycaemic progression in patients
525 with schizophrenia or bipolar disorder. *BJ Psych. Open* 4, 454–460.
526 <https://doi.org/10.1192/bjo.2018.56>.
- 527 Kusumi, I., Boku, S., Takahashi, Y., 2014. Psychopharmacology of atypical antipsychotic
528 drugs: From the receptor binding profile to neuroprotection and neurogenesis.
529 *Psychiatry Clin. Neurosci.* 69, 243–258. <https://doi.org/10.1111/pcn.12242>.
- 530 Kusumi, I., Ito, K., Honda, M., Hayashishita, T., Uemura, K., Hashimoto, N., Murasaki, M.,
531 Atsumi, Y., Kadowaki, T., Koyama, T., 2011. Screening for diabetes using Japanese

- 532 monitoring guidance in schizophrenia patients treated with second-generation
533 antipsychotics: A cross-sectional study using baseline data. *Psychiatry Clin. Neurosci.*
534 65, 349–355. <https://doi.org/10.1111/j.1440-1819.2011.02218.x>.
- 535 Lindström, L., Lindström, E., Nilsson, M., Höistad, M., 2017. Maintenance therapy with
536 second generation antipsychotics for bipolar disorder – A systematic review and meta-
537 analysis. *J. Affect. Disord.* 213, 138–150. <http://doi.org/10.1016/j.jad.2017.02.012>.
- 538 Loredana Marcovecchio, M., 2017. Complications of acute and chronic hyperglycemia review
539 diabetes. *Cit. US Endocrinol.* 13, 1–5.
- 540 Mamakou, V., Hackinger, S., Zengini, E., Tsompanaki, E., Marouli, E., Serafetinidis, I.,
541 Prins, B., Karabela, A., Glezou, E., Southam, L., Rayner, N.W., Kuchenbaecker, K.,
542 Lamnissou, K., Kontaxakis, V., Dedoussis, G., Gonidakis, F., Thanopoulou, A.,
543 Tentolouris, N., Zeggini, E., 2018. Combination therapy as a potential risk factor for
544 the development of type 2 diabetes in patients with schizophrenia: The GOMAP study.
545 *BMC Psychiatry* 18, 249. <https://doi.org/10.1186/s12888-018-1826-4>.
- 546 Marvanova, M., 2013. Strategies for prevention and management of second generation
547 antipsychotic-induced metabolic side effects. *Mental Health Clinician* 3, 154–
548 161. <https://doi.org/10.9740/mhc.n166832>.
- 549 Matsui-Sakata, A., Ohtani, H., Sawada, Y., 2005. Receptor occupancy-based analysis of the
550 contributions of various receptors to antipsychotics-induced weight gain and diabetes

- 551 mellitus. *Drug Metab. Pharmacokinet.* 20, 368–
552 378. <https://doi.org/10.2133/dmpk.20.368>.
- 553 Montastruc, F., Palmaro, A., Bagheri, H., Schmitt, L., Montastruc, J.L., Lapeyre-Mestre, M.,
554 2015. Role of serotonin 5-HT_{2C} and histamine H₁ receptors in antipsychotic-induced
555 diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase.Eur.
556 *Neuropsychopharmacol.* 25, 1556–1565.
557 <https://doi.org/10.1016/j.euroneuro.2015.07.010>.
- 558 Mukherjee, S., Decina, P., Bocola, V., Saraceni, F., Scapicchio, P.L., 1996. Diabetes mellitus
559 in schizophrenic patients. *Compr. Psychiatry* 37, 68–73. [https://doi.org/10.1016/s0010-](https://doi.org/10.1016/s0010-440x(96)90054-1)
560 [440x\(96\)90054-1](https://doi.org/10.1016/s0010-440x(96)90054-1).
- 561 Olfson, M., Gerhard, T., Huang, C., Crystal, S., Stroup, T.S., 2015. Premature mortality
562 among adults with schizophrenia in the United States. *JAMA Psychiatry* 72, 1172–
563 1181. <https://doi.org/10.1001/jamapsychiatry.2015.1737>.
- 564 Padwal, R., Laupacis, A., 2004. Antihypertensive therapy and incidence of type 2 diabetes: a
565 systematic review. *Diabetes Care* 27, 247-255.
566 <https://doi.org/10.2337/diacare.27.1.247>.
- 567 Philibin, S.D., Walentiny, D.M., Vunck, S.A., Prus, A.J., Meltzer, H.Y., Porter, J.H., 2009.
568 Further characterization of the discriminative stimulus properties of the atypical
569 antipsychotic drug clozapine in C57BL/6 mice: Role of 5-HT(2A) serotonergic and

- 570 alpha (1) adrenergic antagonism. *Psychopharmacol. (Berl.)* 203, 303–315.
- 571 <https://doi.org/10.1007/s00213-008-1385-3>.
- 572 Pillinger, T., McCutcheon, R.A., Vano, L., Mizuno, Y., Arumham, A., Hindley, G., Beck,
573 K., Natesan, S., Efthimiou, O., Cipriani, A., Howes, O.D., 2020. Comparative effects
574 of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of
575 metabolic dysregulation, and association with psychopathology: A systematic review
576 and network meta-analysis. *Lancet Psychiatry* 7, 64–77. [http://doi.org/10.1016/S2215-](http://doi.org/10.1016/S2215-0366(19)30416-X)
577 [0366\(19\)30416-X](http://doi.org/10.1016/S2215-0366(19)30416-X).
- 578 Preiss, D., Seshasai, S.R., Welsh, P., Murphy, S.A., Ho, J.E., Waters, D.D., DeMicco, D.A.,
579 Barter, P., Cannon, C.P., Sabatine, M.S., Braunwald, E., Kastelein, J.J., de Lemos, J.A.,
580 Blazing, M.A., Pedersen, T.R., Tikkanen, M.J., Sattar, N., Ray, K.K., 2011. Risk of
581 incident diabetes with intensive-dose compared with moderate-dose statin therapy: a
582 meta-analysis. *JAMA* 305, 2556–2564. <http://doi.org/10.1001/jama.2011.860>.
- 583 Reynolds, G.P., Kirk, S.L., 2010. Metabolic side effects of antipsychotic drug treatment--
584 pharmacological mechanisms. *Pharmacol. Ther.* 125, 169–179.
585 <http://doi.org/10.1016/j.pharmthera.2009.10.010>.
- 586 Silvestre, J.S., Prous, J., 2005. Research on adverse drug events. I. Muscarinic M3 receptor
587 binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.

- 588 Methods Find. Exp. Clin. Pharmacol. 27, 289–304.
- 589 <http://doi.org/10.1358/mf.2005.27.5.908643>.
- 590 Starrenburg, F.C.J., Bogers, J.P.A.M., 2009. How can antipsychotics cause diabetes mellitus?
- 591 Insights based on receptor-binding profiles, humoral factors and transporter proteins.
- 592 Eur. Psychiatry 24, 164–170. <http://doi.org/10.1016/j.eurpsy.2009.01.001>.
- 593 Steardo, L. Jr., Fabrazzo, M., Sampogna, G., Monteleone, A.M., D'Agostino G, Monteleone
- 594 P, Maj, M. 2019. Impaired glucose metabolism in bipolar patients and response to
- 595 mood stabilizer treatments. J Affect Disord. 15, 174-179.
- 596 <http://doi.org/10.1016/j.jad.2018.10.360>.
- 597 Sugai, T., Suzuki, Y., Yamazaki, M., Shimoda, K., Mori, T., Ozeki, Y., Matsuda, H.,
- 598 Sugawara, N., Yasui-Furukori, N., Minami, Y., Okamoto, K., Sagae, T., Someya, T.
- 599 2016. High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes
- 600 Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey. PLoS
- 601 One. 11, e0166429. <http://doi.org/10.1371/journal.pone.0166429>.
- 602 Sweileh, W.M., Dalal, S.A., Zyoud, S.H., Al-Jabi, S.W., Al-Ali, I., 2013. Diabetes mellitus in
- 603 patients with schizophrenia in West-Bank, Palestine. Diabetes Res. Clin. Pract. 99,
- 604 351–357. <http://doi.org/10.1016/j.diabres.2012.12.014>.

- 605 Tabák, A.G., Herder, C., Rathmann, W., Brunner, E.J., Kivimäki, M., 2012. Prediabetes: a
606 high-risk state for diabetes development. *Lancet* 379, 2279–2290.
607 [http://doi.org/10.1016/S0140-6736\(12\)60283-9](http://doi.org/10.1016/S0140-6736(12)60283-9).
- 608 Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., Majak, M., Mehtälä, J., Hoti, F.,
609 Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., Tiihonen, J., 2018.
610 Antipsychotics and mortality in a nationwide cohort of 29,823 patients with
611 schizophrenia. *Schizophr. Res.* 197, 274–280.
612 <https://doi.org/10.1016/j.schres.2017.12.010>.
- 613 Tu, T.H., Huang, K.L., Bai, Y.M., Hsu, J.W., Su, T.P., Li, C.T., Tsai, S.J., Lin, W.C., Chen,
614 T.J., Chen, M.H., 2019. Exposure to second-generation antipsychotics and risk of type
615 2 diabetes mellitus in adolescents and young adults: A nationwide study in Taiwan. *J.*
616 *Clin. Psychiatry* 80; 2012: 18m12284, <https://doi.org/10.4088/JCP.18m12284>.
- 617 Ulcickas Yood, M., DeLorenze, G.N., Quesenberry, C.P., Oliveria, S.A., Tsai, A.L., Kim, E.,
618 Cziraky, M.J., McQuade, R.D., Newcomer, J.W., L'italien, G.J., 2011. Association
619 between second-generation antipsychotics and newly diagnosed treated diabetes
620 mellitus: Does the effect differ by dose? *BMC Psychiatry* 11, 197.
621 <https://doi.org/10.1186/1471-244X-11-197>.
- 622 Vancampfort, D., Correll, CU., Galling, B., Probst, M., De Hert, M., Ward, PB., Rosenbaum,
623 S., Gaughran, F., Lally, J., Stubbs, B., 2016. Diabetes mellitus in people with

- 624 schizophrenia, bipolar disorder and major depressive disorder: a systematic review and
625 large scale meta-analysis. *World Psychiatry* 15, 166-
626 74. <https://doi.org/10.1002/wps.20309>.
- 627 Weston-Green, K., Huang, X.F., Deng, C., 2013. Second generation antipsychotic-induced
628 type 2 diabetes: a role for the muscarinic M3 receptor. *CNS Drugs* 27, 1069–
629 1080. <https://doi.org/10.1007/s40263-013-0115-5>.
- 630 World Health Organization, 2013. The ICD-10 classification of mental and behavioural
631 disorders. *Clin. Descr. Diagn. Guidel.* 55, 135–139.
- 632 Wu, C.S., Lai, M.S., Gau, S.S.F., 2015. Complications and mortality in patients with
633 schizophrenia and diabetes: Population-based cohort study. *Br. J. Psychiatry* 207, 450–
634 457. <https://doi.org/10.1192/bjp.bp.113.143925>.
- 635 Wubeshet, Y.S., Mohammed, O.S., Desse, T.A., 2019. Prevalence and management practice
636 of first generation antipsychotics induced side effects among schizophrenic patients at
637 Amanuel Mental Specialized Hospital, central Ethiopia: Cross-sectional study. *BMC*
638 *Psychiatry* 19, 32. <https://doi.org/10.1186/s12888-018-1999-x>.
- 639 Yonemura, K., Miyanaga, K., Machiyama, Y., 1998. Profiles of the affinity of antipsychotic
640 drugs for neurotransmitter receptors and their clinical implication. *kmj* 48, 87–102.
641 <https://doi.org/10.2974/kmj.48.87>.

- 642 Zagozdzon, P., Goyke, B., Wrotkowska, M., 2016. Mortality rates in users of typical and
643 atypical antipsychotics: A database study in Poland. *Drugs Real World Outcomes* 3,
644 345–351. <https://doi.org/10.1007/s40801-016-0084-3>.
- 645 Zhang, Y., Liu, Y., Su, Y., You, Y., Ma, Y., Yang, G., Song, Y., Liu, X., Wang, M., Zhang,
646 L., Kou, C., 2017. The metabolic side effects of 12 antipsychotic drugs used for the
647 treatment of schizophrenia on glucose: A network meta-analysis. *BMC Psychiatry* 17,
648 373. <https://doi.org/10.1186/s12888-017-1539-0>.
- 649